Autolus Therapeutics (AUTL) Releases Q4 2025 Earnings: Revenue Soars but Net Loss Widens

By: Quiver EarningsTracker

Posted: 4 hours ago / March 27, 2026 9:04 p.m. UTC

AUTL

Autolus Therapeutics plc (AUTL) — Q4 2025 results.

Total revenue of $24.3 million, up 83,655.2% year‑over‑year.

Gross profit of -$1.0 million, down 90.8% year‑over‑year.

Operating loss of -$72.5 million, changed -4.5% year‑over‑year.

Net loss attributable to common shareholders of -$90.3 million, a 227.2% increase year‑over‑year.

Diluted loss per share of -$0.34, a 277.8% change year‑over‑year.

Cash flow and liquidity:

Cash used in operating activities: -$67.3 million, up 77.5% year‑over‑year.

Purchases of property, plant and equipment: $0.9 million, down 108.0% year‑over‑year.

Cash and cash equivalents: $104.1 million, down 54.5% year‑over‑year.

Balance sheet and expense items:

Cost of sales: $25.3 million, up 122.5% year‑over‑year.

Total liabilities: $410.9 million, up 15.6% year‑over‑year.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Autolus Therapeutics plc Hedge Fund Activity

We have seen 38 institutional investors add shares of Autolus Therapeutics plc stock to their portfolio, and 57 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP removed 27,147,035 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $44,249,667
FMR LLC removed 7,105,585 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $11,582,103
CITADEL ADVISORS LLC removed 4,884,452 shares (-80.8%) from their portfolio in Q4 2025, for an estimated $9,720,059
MAK CAPITAL ONE LLC added 3,987,727 shares (+15.3%) to their portfolio in Q4 2025, for an estimated $7,935,576
BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 3,361,156 shares (+inf%) to their portfolio in Q4 2025, for an estimated $6,688,700
AXA S.A. removed 3,126,167 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $5,095,652
PRICE T ROWE ASSOCIATES INC /MD/ removed 2,694,202 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $4,391,549

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Autolus Therapeutics plc Analyst Ratings

Wall Street analysts have issued reports on $AUTL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 01/12/2026

To track analyst ratings and price targets for Autolus Therapeutics plc, check out Quiver Quantitative's $AUTL forecast page.

Autolus Therapeutics plc Price Targets

Multiple analysts have issued price targets for $AUTL recently. We have seen 2 analysts offer price targets for $AUTL in the last 6 months, with a median target of $9.5.

Here are some recent targets:

Gil Blum from Needham set a target price of $10.0 on 03/27/2026
Emily Bodnar from HC Wainwright & Co. set a target price of $9.0 on 02/17/2026